Published on 15 June 2026
THIRD SECTION
Application no. 14359/25
B.P.against Bulgaria
lodged on 13 May 2025
communicated on 20 March 2026 and 26 May 2026
The Subject matter of the case and the initial questions to the parties are available in HUDOC.
On 6 May 2026 the applicant made a new complaint to the Court, under Article 34 of the Convention.
ADDITIONAL QUESTIONS
1. Having regard to Article 34 of the Convention, did the respondent State comply with the interim measure indicated by the Court under Rule 39 on 30 May 2025, by which the Court requested the Bulgarian authorities to provide to the applicant the medication (eyedrops) prescribed for treating his glaucoma condition? In particular, did any actions or omissions of the authorities amount to a hindrance to the effective exercise of the applicant’s right of individual application, within the meaning of Article 34, on account of the alleged gaps in the provision of the prescribed eye-drops?
2. Please describe in detail the steps taken by the domestic authorities to implement the Rule 39 indication of 30 May 2025 requiring them to provide the applicant with the prescribed glaucoma eye-drops, including:
• when and how the relevant domestic institutions were informed of the Rule 39 indication;
• what concrete instructions were given, by whom, and on what dates, to ensure that the applicant received his prescribed eye-drops on a continuous basis.
3. For the period from 30 May 2025 until 4 February 2026, please provide a chronological account (with supporting medical records, prescriptions and administration logs) indicating:
• the type, dosage and frequency of the eye-drops prescribed for the applicant’s glaucoma;
• the dates on which the applicant actually received or had access to these eye-drops;
• any periods during which the applicant did not receive or did not have access to the prescribed eye-drops, specifying the exact dates/duration of each such period.
4. For each period in which the applicant did not receive or did not have access to the prescribed eye-drops, please explain:
• the reasons for the interruption;
• what measures, if any, were taken to remedy the interruption, and on what dates.
5. Please provide copies of any medical examinations, ophthalmological assessments or other medical records concerning the applicant’s glaucoma and general ophthalmological condition after 30 May 2025, and indicate whether, in the doctors’ view, any interruption in the supply or administration of the prescribed eye-drops had, or could have had, an impact on the progression of the applicant’s glaucoma, his symptoms, and his overall state of health.
6. If any remedial or follow-up action (such as an internal review, inquiry or other measures) has been taken in relation to the alleged gaps in the provision of the prescribed eye-drops and the Rule 39 indication of 30 May 2025, please describe it and provide any available documentation.